ASX - By Stock
|
PAA |
Re:
NZT gone but hasn't forgotten
|
|
rodad
|
66 |
17K |
12 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
66
|
17K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Top 200 PAA Shareholders as at 28 March 2024
|
|
rodad
|
55 |
14K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
55
|
14K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 200 PAA Shareholders as at 28 March 2024
|
|
rodad
|
55 |
14K |
3 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
55
|
14K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
rodad
|
196 |
35K |
5 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
196
|
35K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
rodad
|
1.1K |
280K |
11 |
09/03/24 |
09/03/24 |
ASX - By Stock
|
1.1K
|
280K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
rodad
|
209 |
48K |
3 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
48K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
rodad
|
1.1K |
280K |
11 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
1.1K
|
280K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
rodad
|
197 |
51K |
12 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
197
|
51K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
rodad
|
58 |
15K |
14 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
15K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
rodad
|
197 |
51K |
12 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
197
|
51K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
rodad
|
197 |
51K |
18 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
197
|
51K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
rodad
|
1.1K |
280K |
7 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
1.1K
|
280K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
rodad
|
323 |
74K |
11 |
04/02/24 |
04/02/24 |
ASX - By Stock
|
323
|
74K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
rodad
|
430 |
106K |
17 |
22/01/24 |
22/01/24 |
ASX - By Stock
|
430
|
106K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
rodad
|
430 |
106K |
18 |
22/01/24 |
22/01/24 |
ASX - By Stock
|
430
|
106K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
rodad
|
98 |
23K |
18 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
98
|
23K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
rodad
|
430 |
106K |
17 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
430
|
106K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Balance of PAAOA holders as at 29 December 2023
|
|
rodad
|
6 |
1.7K |
1 |
02/01/24 |
02/01/24 |
ASX - By Stock
|
6
|
1.7K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust brand name required
|
|
rodad
|
30 |
6.0K |
7 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
30
|
6.0K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
rodad
|
43 |
10K |
6 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
43
|
10K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
rodad
|
87 |
18K |
17 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
87
|
18K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
rodad
|
355 |
67K |
10 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
355
|
67K
|
10
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
rodad
|
12K |
4.2M |
9 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
12K
|
4.2M
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results of Annual General Meeting
|
|
rodad
|
29 |
7.0K |
7 |
24/11/23 |
24/11/23 |
ASX - By Stock
|
29
|
7.0K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
rodad
|
355 |
67K |
4 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
355
|
67K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at Emerging ASX Gems Conference
|
|
rodad
|
82 |
17K |
12 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
82
|
17K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
rodad
|
355 |
67K |
12 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
355
|
67K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of Annual General Meeting & Proxy Form
|
|
rodad
|
6 |
1.7K |
2 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
6
|
1.7K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
rodad
|
79 |
16K |
18 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
79
|
16K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
rodad
|
91 |
18K |
12 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
91
|
18K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
rodad
|
380 |
83K |
13 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
380
|
83K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
rodad
|
380 |
83K |
12 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
380
|
83K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
$1 party
|
|
rodad
|
21 |
4.6K |
9 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
21
|
4.6K
|
9
|
|
ASX - By Stock
|
BOT |
Re:
webinar
|
|
rodad
|
52 |
11K |
3 |
26/09/23 |
26/09/23 |
ASX - By Stock
|
52
|
11K
|
3
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Trading Halt
|
|
rodad
|
316 |
89K |
14 |
25/09/23 |
25/09/23 |
ASX - By Stock
|
316
|
89K
|
14
|
|
ASX - By Stock
|
BOT |
Re:
Ann: BOT Submits FDA New Drug Application for Sofpironium Bromide
|
|
rodad
|
172 |
62K |
21 |
23/09/23 |
23/09/23 |
ASX - By Stock
|
172
|
62K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
rodad
|
144 |
29K |
12 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
144
|
29K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
rodad
|
78 |
20K |
16 |
20/08/23 |
20/08/23 |
ASX - By Stock
|
78
|
20K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
rodad
|
140 |
31K |
7 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
140
|
31K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
rodad
|
140 |
31K |
4 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
140
|
31K
|
4
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
rodad
|
12K |
4.2M |
10 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
12K
|
4.2M
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
rodad
|
218 |
50K |
11 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
50K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
rodad
|
165 |
34K |
8 |
22/07/23 |
22/07/23 |
ASX - By Stock
|
165
|
34K
|
8
|
|
ASX - By Stock
|
BOT |
Re:
Ann: Trading Halt
|
|
rodad
|
208 |
65K |
11 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
208
|
65K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
rodad
|
200 |
41K |
5 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
200
|
41K
|
5
|
|
ASX - By Stock
|
BOT |
Re:
BOT - Anything but charting
|
|
rodad
|
7.9K |
2.9M |
5 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
7.9K
|
2.9M
|
5
|
|
ASX - By Stock
|
BOT |
Re:
Bot Chart
|
|
rodad
|
12K |
4.2M |
16 |
16/07/23 |
16/07/23 |
ASX - By Stock
|
12K
|
4.2M
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
rodad
|
126 |
28K |
19 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
126
|
28K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
rodad
|
126 |
28K |
4 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
126
|
28K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
PAA Chart
|
|
rodad
|
279 |
71K |
4 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
279
|
71K
|
4
|
|